Viiv

ViiV Healthcare

ViiV Healthcare

Pharmaceutical company

Viiv and ViiV redirect here. For other uses, see Viiv (disambiguation).

ViiV Healthcare (/ˈviːv/ VEEV) is a British multinational pharmaceutical company specializing in the research and development of medicines to treat and prevent HIV/AIDS, with its global headquarters in London. The company was created as a joint venture by GSK and Pfizer in November 2009, with both companies transferring their HIV assets to the new company.[1] In 2012, Shionogi joined the company. As of December 2023, 76.5% of the company is owned by GSK, 13.5% by Pfizer and 10% by Shionogi.[2] According to The Financial Times, the company’s co-ownership structure may change depending on the achievement of certain milestones.[1]

Quick Facts Company type, Industry ...

ViiV Healthcare's products have a market share of approximately 32% of the global HIV therapy market, making it the second-largest healthcare company in the sector, after Gilead Sciences.[3]

ViiV Healthcare's global headquarters are in Brentford, Greater London in the United Kingdom, and the company has sites in a number of other countries including the United States, Australia, Belgium, Canada, France, Germany, Italy, Japan, Mexico, the Netherlands, Portugal, Puerto Rico, Russia, Spain and Switzerland.[4]

Products

The company markets 17 products:[5]

Treatment access programs

ViiV Healthcare has stated that it will continue the not-for-profit pricing schemes that Pfizer and GlaxoSmithKline had been involved in prior to the setting up of the company. This program covers all low- and middle-income countries, as well as all of Sub-Saharan Africa.[7]

The company has also granted voluntary licenses to 14 generics companies to enable the low-cost manufacture and sale of generic versions of the company's products in specific countries and/or regions.[7][8]

In March 2020, ViiV Healthcare announced the initiation of a study in partnership with University of South Carolina's Ryan White Program to determine the effectiveness of ride-sharing services in improving access to care for people living with HIV.[9]

See also

References

  1. [1]
    Jacks, Andrew "GSK and Pfizer to Merge HIV Portfolios Financial Times. 16 April 2010 (subscription required)
  2. [2]
    "Shionogi and ViiV Healthcare Announce New Agreement to Commercialise and Develop Integrase Inhibitor Portfolio". viivhealthcare.com. Retrieved 7 March 2014.
  3. [3]
    "ViiV vows joint venture will help fight HIV". www.ft.com. Retrieved 3 November 2023.
  4. [4]
    "ViiV Healthcare Company Website. About Us — Locations" Archived 9 December 2010 at the Wayback Machine Accessed 13 October 2010
  5. [5]
    "Our HIV medicines". Retrieved 10 March 2022.
  6. [6]
    "Generic Rescriptor Availability". Drugs.com. Retrieved 10 March 2022.
  7. [7]
    "ViiV Healthcare Company Website. We Improve Access to Our Medicines" Accessed 12 January 2014
  8. [8]
    Reuters "Glaxo, Pfizer JV Opens HIV Pipeline to Generic Companies" Africa — the Good News. 19 July 2010
  9. [9]
    "ViiV Healthcare initiates study with the University of South Carolina to evaluate the benefits of ride-sharing services on improving access to care for people living with HIV". Olean Times Herald. Retrieved 3 March 2020.
Share this article:

This article uses material from the Wikipedia article Viiv, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.